Alzheimer's disease (AD) is a neurodegenerative disease that disproportionately impacts memory and the hippocampus. However, it is unclear how AD pathology influences the activity of surviving neurons in the hippocampus to contribute to the memory symptoms in AD. One well-understood connection between spatial memory and neuronal activity in healthy brains is the activity of place cells, neurons in the hippocampus that fire preferentially in a specific location of a given environment (the place field of the place cell). In the present study, place cells were recorded from the hippocampus in a recently-developed rat model of AD (Tg-F344 AD) at an age (12-20 months) at which the AD rats showed marked spatial memory deficits. Place cells in the CA2 and CA3 pyramidal regions of the hippocampus in AD rats showed sharply reduced spatial fidelity relative to wildtype (WT) rats. In contrast, spiking activity of place cells recorded in region CA1 in AD rats showed good spatial fidelity that was similar to CA1 place cells in WT rats. Oral administration of the M 1 muscarinic acetylcholine receptor agonist VU0364572 impacted place cell firing rates in CA1 and CA2/3 hippocampal regions, but did not improve the spatial fidelity of CA2/3 hippocampal place cells in AD rats. The results indicated that, to the extent the spatial memory impairment in AD rats was attributable to hippocampal dysfunction, the memory impairment was more attributable to dysfunction in hippocampal regions CA2 and CA3 rather than CA1.
as theta rhythms (e.g., Foster & Wilson, 2007; O'Keefe & Recce, 1993) , which help coordinate bidirectional interactions with adjacent structures such as the entorhinal cortex (Brun et al., 2008; Jeffery, 2007) .
Cells with location-specific firing can be found in all the major subregions of the rat hippocampus (dentate gyrus, CA1, CA2, CA3, and subiculum), but most data have come from CA1 and CA3 pyramidal cells (e.g., Knierim, Lee, & Hargreaves, 2006; Mizuseki, Royer, Diba, & Buzs aki, 2012) . These data have highlighted anatomical and functional differences between CA1 and CA3, differences that are likely important for understanding memory function and dysfunction. For example, CA3 place cells tend to be more stable (e.g., higher correlation in the location-specific firing between the first and last halves of a given session; Mizuseki et al., 2012) , but also more vulnerable to age-related dysfunction (e.g., Wilson, Ikonen, Gallagher, Eichenbaum, & Tanila, 2005) . Hippocampal place cell function in healthy rats has also been linked to memory processes that are disproportionately impaired in AD (Gallagher & Koh, 2011; Griffin & Hallock, 2013; Manns & Eichenbaum, 2009; Moser et al., 2008) . Thus, the study of CA1 and CA3 place cells in rodent models of AD will likely offer important insights about the memory dysfunction associated with early stages of the disease and help to shed light on how these changes relate to changes reported for age-related memory impairments.
Transgenic mouse models of AD have been invaluable for understanding the disease, and prior studies have reported CA1 place cell dysfunction in several different AD mouse models (e.g. Booth et al., 2016; Cacucci, Yi, Wills, Chapman, & O'Keefe, 2008; Cayzac et al., 2015; Cheng & Ji, 2013; Mably, Gereke, Jones, & Colgin, 2017; Morrissette, Parachikova, Green, & LaFerla, 2009; Zhao, Fowler, Chiang, Ji, & Jankowsky, 2014) . However, most studies of place cells in healthy animals have been in rats. Thus, a recently developed rat model of AD (Tg-F344 AD with human genetic mutations APPSwe and PS1DE9; Cohen et al., 2013) has provided a new opportunity to leverage the large rat place cell literature in asking how the activity of hippocampal neurons relate to spatial memory impairments in AD and how interventions might influence this neuronal activity. As they age, these AD rats gradually develop spatial memory impairments as well as many of the pathological hallmarks of the disease in humans-Ab plaques, NFTs of hyperphosphorylated tau, neuroinflammation, and eventually cell death (Cohen et al., 2013) . Thus, physiological studies of hippocampal neuronal activity in these rats offer an opportunity to connect to the extensive body of work on place cells to understand how AD may influence the activity of surviving cells in a key memory region.
Studying place cells in an AD rat model also permits a direct assessment of new potential drug therapies on memory-related neural activity. AD-related memory loss has been associated with death of cholinergic neurons in the basal forebrain, which is the major supplier of acetylcholine (ACh) to the hippocampus and cortex (Bartus, Dean, Beer, & Lippa, 1982) , and many drugs for treating cognitive decline in AD increase ACh levels generally throughout the nervous system (Anand & Singh, 2013) . One avenue for pursuing new treatments has been the development of new cholinergic activators that target only a subset of the endogenous ACh receptors (Conn, Christopoulos, & Lindsley, 2009 ). In particular, the M 1 muscarinic ACh receptor (mAChR) is highly expressed in brain regions important for memory, including the hippocampus, and is less implicated in the dose-limiting peripheral side-effects caused by global ACh activation (Bymaster et al., 2003; Levey, Kitt, Simonds, Price, & Brann, 1991) . Moreover, a recentlydeveloped M 1 mAChR agonist, VU0364572, improved memory (Digby et al., 2012) and influenced place cells in healthy young rats after acute administration (Lebois, Trimper, Hu, Levey, & Manns, 2016) , and reduced amyloid pathology and memory deficits in a mouse model of AD after chronic administration (Lebois et al., 2017) . Thus, an important question is how acute administration of the M 1 agonist VU0364572
would influence place cell function in a rat model of AD.
The goal of the present study was to characterize the neural correlates of spatial memory dysfunction in a rat model of AD and to ask if oral administration of the M 1 mAChR agonist VU0364572 might ameliorate any such dysfunction. In Experiment 1, we tested memory performance monthly in AD rats and their wild-type (WT) littermates, and found that AD rats developed marked spatial memory impairments by 12 months of age. In Experiment 2, we recorded the activity of hippocampal place cells as 12-20 month-old AD and WT rats completed laps around a circular track after oral administration of either the M 1 agonist VU0364572 or a control vehicle. This age range was selected to occur when the AD rats were known to have a spatial memory impairment (Experiment 1) and amyloid load and tau pathology were present but still increasing (Cohen et al., 2013) . Despite showing marked spatial memory impairments, several features of hippocampal place cell activity in AD rats were similar to that of WT rats in the vehicle control condition. Notably, spiking activity of place cells recorded in region CA1
showed good spatial fidelity that was similar to CA1 place cells in WT rats. In contrast, spiking activity of place cells in the CA2 and CA3 pyramidal regions of the hippocampus in AD rats showed sharply reduced spatial fidelity relative to WT rats. Administration of the M 1 agonist VU0364572 impacted place cell firing rates in CA1 and CA2/3 place cells but did not improve the spatial fidelity of CA2/CA3 hippocampal place cells in AD rats.
| EX PE R IM E N T 1 2.1 | Materials and methods

| Subjects
Sixteen female Fisher 344 rats were tested each month from 5-12 months of age. Eight rats expressed the human genetic mutations APP Swe and PS1DE9 (Tg-F344 [AD]), and eight rats were WT littermates (F344 [WT] ). Female rats were used because, as compared to male rats (and irrespective of whether they were in the AD or WT group), female rats were found in pilot testing to much more readily engage in spontaneous object exploration, a necessary prerequisite for object recognition memory testing (see "Section 2.1.2"). Extensive characterization of AD-related neuropathology for the Tg-F344 (AD) rats is available in Cohen et al. (2013) , which reported no sex effects. The rats were kept on a 12-h light/dark cycle (testing occurred during the light period) and were individually housed with free access to water and food. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Emory University.
| Procedure
Memory was tested monthly in each rat from 5 to 12 months of age using two variants of a widely-used novel object recognition memory task (Clark & Squire, 2010; Ennaceur & Delacour, 1988 ) that takes advantage of the innate novelty preference of rats (see below for details specific to the object and object-in-location variants). The AD rats were previously found to have impaired spatial memory performance at 16 months of age (Cohen et al., 2013) , but time points between 6 and 16 months of age were not previously assessed. Several studies in human AD patients and transgenic rodent models have found that AD may particularly impair spatial associative memory, such as the ability to remember the location of a previously encountered object (Good, Hale, & Staal, 2007; Hampstead, Stringer, Stilla, Amaraneni, & Sathian, 2011; Hanaki et al., 2011; Kessels et al., 2010) , and thus one variant of that task was an object-in-location spatial recognition memory task.
For both variants of the recognition memory task, all testing was conducted in an open box (91.5 by 91.5 cm wide and 61.0 cm tall) made of wood and painted black. Four Velcro patches (2.5 cm by 2.5 cm) were affixed to the midpoints of the four quadrants of the square floor to secure objects during testing. The objects used in the study ranged in size from approximately 7 by 7 by 7 cm to 17 by 17 by 10 cm and were made from ceramic, wood, plastic, or metal. New objects were used for each test session. One month prior to testing (at 4 months of age) rats were habituated to the testing box by allowing them to spend 10 min per day in the box for three consecutive days.
Approximately one week (4-10 days) prior to testing, rats were habituated again to the box for 10 min on a single day. For each subsequent month of testing, rats were re-habituated to the box for 5 min 1 day prior to testing. On every testing day, rats were also allowed to spend 5 min in the empty box immediately prior to the test session. The floor of the box was cleaned with 100% ethanol after each session. For each month of testing, rats completed two sessions of an object recognition memory task within the same day (elapsed time between sessions ranged from 1 to 3 h), followed by two sessions of an object-inlocation recognition memory task the next day. Every rat was tested by the same experimenter who was blind to the genotype of each rat. Figure F1 1 shows the testing procedure of example trials for both tasks, and procedures specific to each task are described below.
| Object recognition memory task
For the study phase of the object recognition memory task, rats were placed in the testing environment for 3 min with two novel objects positioned in two of four possible quadrants of the square floor (different quadrant locations were used across the two trials administered to a rat each month). Rats were then placed back into their home cage for a 2-min delay between the study and test phase. This delay length was chosen because previous studies have shown that the performance of rats on similar location-based object recognition tasks with comparable delays was sensitive to hippocampal damage (e.g. Save, Poucet, Foreman, & Buhot, 1992) . For the test phase of the task, rats were placed back into the testing environment for 3 min with a duplicate of one of the study phase objects (the 'repeated' object) and one novel object.
The repeated object occupied the same location as it did in the study phase, and the novel object was positioned in the same location as the object it replaced from the study phase. Assignment of objects and quadrant locations to conditions was counterbalanced across rats.
| Object-in-location recognition memory task
For the study phase of the object-in-location recognition memory task, rats were placed into the testing environment for 3 min with three novel objects placed in three of four possible quadrants of the square floor (different quadrant locations were used across the two trials administered to a rat each month). Rats were then placed back into their home cage for a 2-min delay between the study and test phase.
For the test phase of the task, rats were placed back into the testing environment with duplicates of each object from the study phase. One of these duplicates was placed in the same location as it had appeared during the study phase (the 'repeated location' object), and two of the duplicates were placed in swapped locations (the 'novel location' objects). Assignment of objects and quadrant locations to conditions was counterbalanced across rats.
| Analyses
Each study and test session was digitally recorded (30 frames per second) by a video camera mounted to the ceiling of the testing room.
Onset and offset of each bout of object exploration during the test FIGURE 1 Schematic of procedures for the object and object-inlocation recognition memory tasks. Each trial of both tasks included a study phase and a test phase. For the object recognition memory task, rats encountered two novel objects during the study phase, then a duplicate of one of the study objects and a different novel object during the test phase. For the object-in-location memory task, rats encountered three novel objects during the study phase and three duplicates of the study phase objects during the test phase. One duplicate was placed in the same location as it appeared during the study phase, and two duplicates swapped locations. Rats completed two trials of each task each month from 5 to 12 months of age. Unique novel objects were used for each trial, and locations were counterbalanced across trials (see "Section 2.1" for details) phase were scored separately by an experimenter who was blind to both rat genotype and to which condition an object was assigned (e.g., repeated or novel condition). Object exploration was defined as active exploration (e.g., sniffing and whisking) within 1 cm of the object that excluded chewing or rearing on or nearby the objects. For both tasks, a discrimination index (DI) was calculated from the mean raw exploration times of rats during the test phase as a measure of memory performance (DI 5 mean novel exploration/([mean novel exploration 1 mean repeated exploration]). For each month, the relative memory performance of WT and AD rats was determined by calculating the mean of each rat's DI for both sessions of each task for that month, and then calculating the mean DI across rats of each genotype. For the objectin-location task, the mean exploration of the two objects in novel locations was entered into the DI calculation for that session. Trials in which a rat did not explore the to-be-repeated object (or the to-berepeated object location for the object-in-location task) during the study phase were excluded from analyses. Trials in which a rat did not explore at least one second across all objects in the test phase were excluded from analyses. Due to the month-to-month variability in mean DI scores for both genotypes (likely attributable to the scores being based on only two trials per month), analyses focused on the 4 month averages to determine age-related differences between WT and AD rats. Analyses focused on genotype differences between tasks and age groups (5-8 months vs. 9-12 months).
| Results
2.2.1 | AD rats showed age-dependent spatial memory impairments relative to WT rats Figure  F2 2 shows memory scores (as DIs; see Section 2.1) for AD and WT rats on both the object and object-in-location recognition memory tasks. The results are shown for the mean DIs of each genotype across 5-8 months of age and 9-12 months of age. A three-way (2 3 2 3 2) One potential concern was that AD rats may have spent less time exploring and forming memories of objects relative to WT rats.
Although exploration times of objects during the study phase for both tasks declined over the months of testing for both AD and WT rats (M 6 SEM: 5-8 months WT 5 27.2 6 4.5 s; 9-12 months WT 5 11.9 6 2.7 s; 5-8 months AD 5 28.8 6 2.0 s; 9-12 months AD 5 10.7 6 2.1 s), exploration times during the study phase were similar between AD and WT rats (F[1,14] 5 0.54, p 5 .47, h p 2 5 0.04). Moreover, the spatial memory impairment of AD rats relative to WT rats at 9-12 months of age remained significant even when study exploration was included as a covariate (F[1,14] 5 7.51, p < 0.05, h p 2 5 0.37).
One unexplained aspect of the data was the poor performance by the WT rats on the object recognition memory task at 9-12 months of age. These same WT rats performed well at the same age on the object-in-location recognition memory task, which depends in part on having an intact memory of a specific object, and thus the combined data suggest that the WT rats likely were capable of good object recognition memory at this age. In any case, the AD rats showed a clear spatial memory deficit at 9-12 months of age but no evidence that they were impaired relative to WT rats on the nonspatial object task at this age. This finding suggests that brain regions important for spatial memory performance in AD rats are impaired by 9-12 months of age.
| Interim summary
The results of Section 2 indicated that AD rats had intact non-spatial and spatial recognition memory at 5-8 months of age but developed a spatial memory impairment relative to WT rats between 9 and 12 months of age. [AD]), and 9 were wild type (WT) littermates. Eleven rats (7 AD and 4
WT) yielded useable neural data. For these rats, testing occurred when the rats were 12-20 months of age (WT M 5 15.5, AD M 5 17.0), an age range at which the AD rats were known to have a spatial memory impairment (Experiment 1) and moderate levels of neuropathology (Cohen et al., 2013) . One WT and four AD rats were used in a longitudinal behavioral experiment (Experiment 1) that ended several months prior to Experiment 2. The rats were kept on a 12-h light/dark cycle (testing occurred during the light period), individually housed with free access to water, and placed on a restricted diet such that they maintained at least 90% of their free-feeding weight. All experimental procedures were approved by the Institutional Animal Care and Use
Committee of Emory University.
| Drugs
VU0364572 (Lebois et al., 2011) , a highly-selective bitopic agonist of the M 1 muscarinic acetylcholine receptor (mAChR), was used to test the effects of M 1 agonism on the spatial fidelity of hippocampal place cells. VU0364572 was chosen for its selectivity for the M 1 mAChR versus other acetylcholine receptors and other off-target proteins (Lebois et al., 2011) . In addition, prior studies found that VU0364572 possesed good oral bioavailability and brain penetrance (Lebois et al., 2009; . Further, prior studies established an efficacious range of doses for altering in vivo hippocampal function and memory performance in mice and rats (Digby et al., 2012; Galloway, Lebois, Hernandez, Shagarabi, & Manns, 2014; Lebois et al., 2011) . Finally, the drug was not found to impact overt behavior (e.g., run or swim speeds) or lead to classic cholinergic side effects in previous studies (Digby et al., 2012; Galloway et al., 2014; Lebois et al., 2011 Lebois et al., , 2016 . Here, VU0364572
was formulated as an HCl salt in nuclease-free H 2 O, and then mixed into strawberry-flavored gelatin for a total volume of 1.2 mL. Thirty min prior to each testing session, rats were orally administered either 10 mg/kg M 1 agonist, 30 mg/kg M 1 agonist, or vehicle control. The timing of the drug administration was based upon previously published pharmokinetic data with VU0364572, and selected so that the M 1 allosteric agonist would have a high brain concentration throughout the testing session (Lebois et al., 2011) . The specific 10 and 30 mg/kg oral doses were selected for their demonstrated efficacy in altering hippocampal function in healthy young rats (Lebois et al., 2016) .
| Surgery and histology
Each rat underwent surgery using sterile tip technique to affix to the rat's skull a chronic recording assembly with up to 8 tetrodes to record neural activity. A craniotomy was made that centered approximately 3.7 mm posterior and 2.6 mm lateral to the right of bregma. The base of the chronic recording assembly was positioned above this craniotomy so that tetrodes could be independently lowered into the CA1, CA2, and CA3 pyramidal layers of the dorsal hippocampus. Each tetrode consisted of four 12.5 mm nichrome wires. The tips of each tetrode were plated with gold to reduce impedance to 100-200 kX at 1 kHz to facilitate the detection of individual units in the hippocampus.
For general analgesia, rats were injected subcutaneously (s.c.) with 2 mg/kg injectable meloxicam before surgery and anesthetized with 1-3% isoflurane in oxygen throughout surgery. Just prior to a midline incision to reveal the skull, up to 0.1 mL of 0.25% bupivacaine with 1:200,000 epinephrine was administered over 2-3 s.c. injections along the scalp as a local anesthetic. Rats were injected s.c. with 2.5 mL of lactated ringers in each the left and right rear haunch for hydration.
After the skull was exposed, nine stainless-steel screws were secured along the ridges of the skull to serve as an anchor for the recording assembly. One additional stainless steel screw, soldered to a wire attached to the recording assembly, served as the ground and was secured to the posterior portion of the skull above the cerebellum. The base of the chronic recording assembly was secured to the anchor screws with dental acrylic. During surgery, tetrodes were slowly lowered into the brain until they were roughly 1 mm above the target regions. Topical antibiotics were applied to the incision site, and one to three stiches were used to close the scalp around the base of the implanted device. Before rats were removed from anesthesia, they received a second round of s.c. injections of 5 mL of lactated ringers (2.5 mL in each haunch) to help prevent postsurgery dehydration.
For the first two days after surgery, rats were injected s.c with 1 mg/kg of injectable meloxicam. Rats appearing dehydrated were injected s.c. with 5 mL of lactated ringers (2.5 mL in each haunch). Four rats (all from the AD group), instead of injectable meloxicam and local bupivacaine, received s.c. injections of 0.05 mg/kg buprenorphine prior to surgery followed by an oral dose of 0.75 mL meloxicam (0.5 mg/mL) immediately after the rats began to ambulate after surgery. These same four rats, instead of receiving injectable meloxicam first and second day after surgery, were injected s.c. with 0.05 mg/kg buprenorphine and administered an oral dose of .75 mL meloxicam the first day after surgery, and were administered an oral dose of 0.75 mL meloxicam the second day after surgery. The difference in pre-and postoperative analgesia for these rats was related to changes in recommendations by veterinary staff, and genotype was unknown at the time. All rats were given 1 week to recover, and then tetrodes were slowly lowered 20-80 mm at a time into the target regions of the hippocampus using hallmark electrophysiological cues. In order to minimize movement between sessions, tetrodes were not raised or lowered from 24 h prior to the first testing session until the rat was euthanized. After testing was completed and just prior to euthanasia, small lesions were made at the tips of recording electrodes by passing 20-40 mA of direct current for 20 s each. After euthanasia, brains were sectioned into 40 mm-thick coronal slices and stained with cresyl violet to confirm tetrode locations based off of marking lesion location.
| Procedure
The spatial fidelity of hippocampal place cells was assessed for six consecutive days in each rat. All testing was conducted on a circular track (track outside diameter 5 
| Data acquisition and analyses
The locomotion of rats during testing was recorded by a digital video camera mounted to the ceiling of the testing environment at a 30 Hz sampling rate (30 frames per second). After testing, the location of a rat's head on each frame was obtained using custom software or manually by a trained experimenter blinded to rat's genotype and drug condition. Light emitting diodes attached to the recording assembly aided the determination of location. Analyses of neural data are described below, and calculations in each case were based on data collected from the two sessions of each drug condition (10 mg/kg VU0364572, 30 mg/kg VU0364572, and control vehicle). In the rare case when only one session was available for a given drug condition (e.g., due to technical computer-related problems), the values represent the calculations for one session rather than the mean of two sessions.
| Acquisition of spiking data
Spiking activity of single units was recorded at a sampling rate of 30,000 Hz and filtered at 600-6,000 Hz with the NSpike data acquisition system (nspike.sourceforge.net). After testing, spiking data was manually sorted into putative individual neurons using software that permitted a three-dimensional view of spike waveform characteristics (e.g., spike peak amplitude) across any three wires of a tetrode (Offline Sorter, Plexon, Dallas, TX). Putative pyramidal neurons were distinguished from interneurons based on spike waveforms, autocorrelograms, firing rates, and presence of complex spikes, an approach similar to procedures used previously (e.g., Trimper, Galloway, Jones, Mandi, & Manns, 2017) . Too few interneurons were recorded to permit analyses.
Timestamps of sorted pyramidal neuron spiking data were then analyzed with custom MATLAB scripts.
Many prior studies have documented differences in patterns of pyramidal neuron spiking activity between hippocampal regions CA1 and CA3 (e.g., Leutgeb & Leutgeb, 2007; Mizuseki et al., 2012; Oliva, Fern andez-Ruiz, Buzs aki, & Ber enyi, 2016) . The present analyses therefore used data from only tetrodes for which the recording location could be determined by postmortem histology (see Section 3.1.3). Specifically, only data from tetrodes that were confirmed to be located in CA1 were used in analyses of CA1 units. Similarly, data from tetrodes confirmed to be located in CA3 were used in analyses of CA3 units.
Although the primary goal in distinguishing between the hippocampal subregions was to understand whether AD differentially impacted CA1
and CA3 place cells, the location and size of some tetrode tip marking lesions (see Section 3.1.3) made it difficult to distinguish definitively between CA2 and CA3 regions during histological inspection. Thus, data from these tetrodes were combined into one region subsequently referred to as CA2/3.
| Quantification of spatial characteristics of spiking data
The firing rates of hippocampal pyramidal neurons often relate closely to the rat's position in an environment (O'Keefe & Dostrovsky, 1971) .
A main question in the present study was thus whether the spiking activity of CA1 or CA2/3 pyramidal neurons from AD rats would show Stage:
Page: 6 during locomotion rather than stationary moments of consummatory behaviors.
The primary measurement of spatial correlates for each neuron's spiking activity was a calculation of a spatial information score (Skaggs, McNaughton, Wilson, & Barnes, 1996) , a widely-used metric that reflects the spatial fidelity of the neuron's spiking activity. Specifically, spatial information scores reflect the amount of spatial information emitted by each spike in terms of bits per spike, using the formula:
where p i 5 probability the rat was at spatial bin i (out of N bins), R i 5 firing rate at spatial bin i, and R 5 overall firing rate of the place cell (Skaggs et al., 1996) .
Pyramidal cells were further characterized as "place cells" if they had at least one area of the environment (place field) in which the firing rate of the unit preferentially increased when the rat was within that place field relative to other locations in the environment. Place field boundaries were determined by the bins in which the firing rates were at least 10% of the maximum in-field firing rate. Note that this calculation does not exclude the possibility that a given unit could have multiple place fields. However, putative place cells with four or more place fields (10 out of the total 1,112 pyramidal units recorded; 0.9%) were excluded from analyses based on the likelihood that these cells were not typical place cells. Place fields with an area of less than 10 bins or for which more than 10% of the in-field spikes would have occurred within the center stem (where rats consumed the food reward after each lap) were excluded from the analyses to minimize the possibility that spurious activity could be labeled as a place field. In addition, place cells were excluded from analyses if the rat did not traverse its place field (or at least one field if a cell exhibited multiple) on at least half of the laps (e.g., place fields for which spiking was visible only when the rat leaned its head to the side of the track).
A second main approach to quantifying the spatial fidelity of place cells was based on the idea that spiking inside a place field represented spatial signal whereas spiking outside a place field represented noise. In particular, a ratio was calculated for each neuron based on the relative proportion of spiking occurring inside versus outside a place field.
Overall out-of-field firing rates for each place cell were calculated using all spikes not occurring inside any field while rats were running laps.
For each place cell, a proportion of in-field firing was then calculated using the following formula: mean in-field firing rate/(mean in-field firing rate 1 mean out-of-field firing rate). For place cells with more than one place field, the mean in-field firing rate was based on an average across fields. Spiking activity inside place fields occupying the center of the stem or for which rats traversed on less than half of the laps were excluded from analyses.
| Local field potential acquisition and analysis
In addition to the spiking data, local field potentials (LFPs) were recorded from one tetrode in CA1 and one tetrode in CA3 in each session (useable data for CA1 was not available for one AD rat Mitra, 2010) . Power was calculated using multitaper fast Fourier transforms (Bokil et al., 2010) . To minimize complications that can arise when assuming oscillatory data is stationary (Mitra & Pesaran, 1999) , spectral estimates of the LFPs were calculated in time windows of 0.5 s. Power estimates of CA1 and CA3 were log10 transformed then multiplied by 10 to convert from bels to decibels, and bias corrected to allow for statistical comparison. The analyses focused on theta (7-9 Hz), slow gamma (30-55 Hz), and fast gamma frequency ranges based on the prominence of these oscillations in the hippocampus (Colgin et al., 2009 ) and possible relation to AD-related hippocampal dysfunction (e.g. Mably et al., 2017) . For the slow gamma and fast gamma frequency bands, we used 5 tapers so that the spectral estimates for each frequency was averaged across 66 Hz. For the theta frequency band, we used 1 taper so that spectral estimates were averaged across 62 Hz. The relationship between time window (T), frequency range half bandwidth (W), and number of tapers (K) is specified by the formula: K 5 2TW21 (Mitra & Pesaran, 1999) .
LFP power spectra as rats were completing laps on the circle track were analyzed as a function of the rat's speed of locomotion because both theta and gamma oscillations have been shown to correlate with locomotion speed (Ahmed & Mehta, 2012) . Locomotion speeds were calculated by the frame-to-frame change in the x and y coordinates of the rat within a session and were split into three bins (stationary 5 1-12 cm/s, slower running 5 13-25 cm/s, faster running 5 26-62 cm/ s). Power was calculated from the data within each running bin separately and then averaged. The number of 0.5-s sweeps in each run bin for different rats and different run bins was variable, and a low number of sweeps can upwardly bias spectral estimates. Thus, we found the minimum number of 0.5-s sweeps for each rat over all sessions and run bins. Then for each run bin within a session for a given rat, we subsampled from the total sweeps in that run bin 500 different times, and calculated spectral estimates using that rat's minimum sweep number of randomly scrambled sweeps. The final power for one run bin of one session of one rat reflects the mean across all 500 subsamples. This approach minimized the possibility that differing locomotion speeds between sessions would have determined spectral results. Gamma power is shown from data collected when rats were stationary, and theta power is shown from data collected when rats were not stationary.
3.1.9 | Spike-phase modulation acquisition and analysis
In order to evaluate the depth of spike modulation in CA1 and CA2/3 place cells relative to CA1 theta, CA1 theta phase was obtained using a waveform-based method (see Trimper et al., 2017) and the phase of theta for each spike of CA1 and CA2/3 place cells was calculated using an open-source circular statistics toolbox for MATLAB (Berens, 2009) to obtain the mean resultant vector length for each place cell.
| Adjusting data for age
The age at testing varied across rats (range: 12-20 months) in part due to data collection bottlenecks inherent to single-unit in vivo electrophysiology. In order to account for the possibility that hippocampal activity was influenced by age in both AD and WT rats, age-adjusted values for each place cell metric (spatial information scores, in-field firing rates, proportion of in-field firing), LFP power, and spike-field mean resultant length were calculated by first regressing each variable with rat age in months (including data from both AD and WT rats in one model) and by then adding the residuals to the original grand mean.
This approach is similar to including age as a covariate in each ANOVA and was taken to minimize the possibility that the slightly older age of the AD rats (mean age 5 17.0 vs. 15.5 months for WT) did not disadvantage their data. As one example of the approach, a linear regression of spatial information scores by age revealed a statistically significant effect of age (F[1,1100] 5 66.19, p < .001; R 2 5 .06), although the effect was modest (b for age 5 -0.095; each month of age corresponding to a 0.095 lower spatial information score on average). Figure  F3  3 shows these spatial information scores plotted for each pyramidal neuron by the rat's age before and after adjusting for age. Although the data are similar after adjusting for age, the adjustment was an important analysis step. All plotting and statistical analyses were conducted with age-adjusted values unless noted otherwise. Table  T1 1 shows the number of CA1 and CA2/3 pyramidal cells and place cells recorded from 4 WT and 7 AD rats for the control and drug conditions. Figure  F4 4 shows example CA1 and CA2/3 place field plots for WT 
| Results
| Hippocampal CA2/3 but not CA1 place cells of AD rats showed impaired spatial fidelity
A main question of interest was whether place cell activity might differ between AD and WT rats or across drug conditions. Many studies have found differences between CA1 and CA3 place cell characteristics (Leutgeb & Leutgeb, 2007; Mizuseki et al., 2012) Table   1 for detailed statistics). However, the difference between spatial information scores for AD and WT rats depended on whether the place cells were recorded in CA1 or CA2/3 (genotype 3 region interaction: F [1,1100] 5 20.04, p < .001). Indeed, the CA1 spatial information scores for AD rats were similar to those of WT rats, but the CA2/3 spatial information scores for AD rats were markedly lower than those of WT rats. Supporting Information Figure 1 replots the AD data as a 0.14, 2.35 6 0.14, 2.47 6 0.14 for control, 10 mg/kg VU0364572, and 30 mg/kg VU0364572; CA3 AD 5 1.53 6 0.12, 1.85 6 0.12, 1.90 6 0.12 for control, 10 mg/kg VU0364572, and 30 mg/kg VU0364572).
An overall three-way ANOVA (genotype by region by drug condition) again identified a significant genotype by hippocampal region interaction (F[2,798] 5 16.04, p < .001).
3.2.3 | M 1 agonism influenced AD and WT hippocampal place cell in-field firing rates but not ratios of in to out-of-field firing rates
We next asked if more direct measures of spiking activity might further inform possible differences between AD and WT rats or reveal the influence of drug administration. In particular, we calculated for each place cell the average firing rate inside versus outside a cell's place field(s) based on the idea that in-field spiking might represent a signal regarding the rat's location whereas out-of-field spiking might represent noise. Figure 5B shows for AD and WT rats the mean in-field firing rates for CA1 and CA2/3 place cells in the control and drug conditions (see also Supporting Information Figure 1B for plots of the AD data normalized to WT data). In general, for both CA1 and CA2/3 place cells, oral administration of the M 1 -selective mAChR agonist VU0364572 increased in-field firing rates for WT rats but decreased in-field firing rates for AD rats. An overall three-way ANOVA (genotype by region by drug condition) for in-field firing rates identified significant genotype by drug interaction (F[2,1100] 5 3.49, p < .05; see Supporting
Information Table 2 ). Additional two-way (hippocampal region by genotype) ANOVAs were conducted separately for the control and drug conditions (see Supporting Information Table 2 ). In contrast to the pattern of results from spatial information scores, the in-field firing rates of CA1 and CA2/3 place cells did not significantly differ between AD and WT rats in the control condition (p 5 .33) but diverged with oral administration of the M 1 -selective mAChR agonist VU0364572, particularly at the higher 30 mg/kg dose (p < .05).
We next sought to address the discrepancy between the pattern of results from in-field firing rates and spatial information scores by asking if a proportion of in-field (signal) and out-of-field (noise) firing rates might correspond better to a place cell's spatial fidelity rather than absolute in-field firing rates. Figure 5C shows this proportion of in-field firing (calculated as: mean in-field/[mean in-field 1 mean outof-field]) for CA1 and CA2/3 place cells for AD and WT rats across control and drug conditions (see also Supporting Information Figure 1C for plots of the AD data normalized to WT data). The pattern of results closely resembled those observed with spatial information scores. Specifically, the CA1 ratios for AD rats were very similar to those of WT rats, the CA2/3 ratios for AD rats were markedly lower than those of WT rats, and there was no overall apparent effect of drug condition.
An overall three-way ANOVA (genotype by region by drug condition) 3.2.4 | CA2/3 but not CA1 place fields were larger in AD rats as compared to WT rats
We next asked if the reduced spatial fidelity of CA2/3 place cells in AD rats relative to WT rats was related to larger place fields and/or an increased number of place fields per cell. Table  T2  2 Table 4 ). The mean number of place fields per CA1 and CA2/3 place cell was close to 1 across drug conditions for AD and WT rats (range 5 1.11-1.32). An overall three-way ANOVA (genotype by region by drug condition) identified no significant overall effects of genotype, region, or drug condition (all ps > .1), yet did result in a significant interaction between genotype and drug condition (F[1,1100] 5 4.77, p < .01; see Supporting Information Table 5 ). Thus, place field size paralleled spatial information scores in identifying dysfunction in AD rats specific to CA2/3, whereas the number of fields per place cell paralleled absolute in-field rates in identifying divergent effects of M 1 agonism on place cell activity in AD versus WT rats.
3.2.5 | M 1 agonism influenced theta modulation of spiking differently for AD and WT place cells Neuronal oscillations are important to normal place cell function, and thus we next asked whether theta or gamma oscillations differed between AD and WT rats or were influenced by administration of the M 1 -selective mAChR agonist, VU0364572. Table  T3 3 shows the mean power (dB) of theta (7-9 Hz), slow gamma (30-55 Hz) and fast gamma (65-90 Hz) oscillations in CA1 and CA3 pyramidal cell layers for AD (n 5 5) and WT (n 5 4) rats with LFP data from both hippocampal regions across the control and drug conditions. The mean CA1 and CA3 power for theta, slow gamma, and fast gamma was similar for AD and WT rats and was not significantly influenced by drug administration (three-way ANOVAs: all ps > .1; see Supporting Information Tables   6, 7 , and 8). One important consideration for these results is that oscil- Figure 5D shows the mean resultant lengths for CA1 and CA2/3 place cells from AD and WT rats across control and drug conditions (see also Supporting Information Figure 1D for plots of the AD data normalized to WT data). An overall three-way ANOVA (genotype by region by drug condition) identified an effect of region (F[1,898] 5 39.87, p < .001), reflecting a general tendency of CA2/3 place cell spiking to be more strongly modulated by theta relative to CA1 (see Supporting Information Table 9 ). The results also 11.62, p < .01) but not in the control or 10 mg/kg M 1 agonist conditions (ps > .10; see Supporting Information Table 9 ). These results resemble the trends observed for CA1 and CA2/3 in-field firing rates and number of fields per cell insofar as administration of the M 1 -selective mAChR agonist VU0364572 led to differences between WT and AD rats that did not exist in the control condition.
3.2.6 | Impact of adjusting data for rat age
All of the results for Experiment 2 reported above were adjusted to take account of rats' age (see "Section 3.1.10"). This procedure was an important step taken to minimize the possibility that the AD rats' slightly higher age (mean 5 17.0 months) as compared to the age of WT rats (mean 5 15.5 months) did not lead to spuriously decreased estimates of hippocampal activity in the AD rats. Nevertheless, we also recalculated all of the results without accounting for rats' age and Tables 1-9 except that Supporting   Information Tables 10-18 report results when data were not adjusted for rats' age. The pattern of results between AD and WT rats and across drug conditions are similar whether or not the data were adjusted for age. For example, regardless of age-adjustment, spatial information scores across drug conditions for CA2/3 place cells were lower for AD rats as compared to WT rats, whereas for CA1 place cells were similar between groups of rats (see Figure 5A , Supporting Information Figure 2A , and Supporting Information Tables 1 and 10 ). Thus, adjusting for age was an important step in the analyses to ensure that lower AD scores were not attributable to a slightly older age, but the age adjustment did not introduce substantial differences in the pattern of results.
| G EN ER A L DISCU SSION
The results of Experiment 1 indicated that AD rats showed impaired spatial memory relative to WT rats by 9-12 months of age. The results of Experiment 2 indicated that, to the extent that this memory impairment was related to dysfunction in the hippocampus, it was more attributable to dysfunction in regions CA2 and CA3 rather than CA1.
Specifically, we investigated how hippocampal place cell function differed between AD and WT rats who were at least 12 months of age (but no older than 20 months) and found that spatial fidelity of hippocampal place cells was impaired in AD rats for CA2/3 pyramidal neurons but not CA1 pyramidal neurons. Other measures of hippocampal function, such as the power of theta and gamma oscillations in the CA1 and CA3 LFPs, were similar between AD and WT rats, suggesting that the spatial memory impairment was more closely related to place cell dysfunction as compared to these other measures. The results also indicated that oral administration of an M 1 -specific mAChR agonist (VU0364572) influenced firing rates and depth of spike theta phase modulation of hippocampal place cells in both AD and WT rats but did not improve the reduced spatial fidelity of CA2/3 place cells in AD rats.
These results are considered in more detail below.
4.1 | Specificity of hippocampal place cell dysfunction in a rat model of AD By 9-12 months of age, the AD rats showed impaired spatial memory performance that was no better than one would expect by chance (Figure 2) . Despite this marked memory impairment, no differences between AD and WT rats aged 12-20 months were observed in any measure of CA1 place cell activity or local field potentials in the absence of drug administration ( Figure 5 ; Tables 2 and 3 ). In contrast, CA2/3 place cells in AD rats showed reduced spatial information scores ( Figure 5 ), lower proportions of in-field firing ( Figure 5 ), and increased place field size (Table 2) relative to CA2/3 place cells in WT rats in the control condition. The type of spatial memory assessed by the objectin-location memory task is known to depend on the hippocampus (Barker & Warburton, 2011) , and thus one main implication is that it was possible that the spatial memory impairment exhibited by AD rats in the present study was due at least in part to the reduced spatial fidelity of place cells in hippocampal regions CA2 and/or CA3. An important caveat to this interpretation is that the reduced spatial fidelity of CA2/3 place cells in Experiment 2 were observed outside the context of an explicit memory task and cannot be causally linked to the spatial memory deficits in Experiment 1. A related second point is that CA1 place cell function was spared in AD rats aged 12-20 months. A prior study that extensively characterized the neuropathology of the AD rats (Cohen et al., 2013) found that, by 16 months of age (close to the mean age of rats in the present study at the time of recording), AD rats showed throughout the hippocampus and neocortex significantly increased markers of Ab deposits, tau pathology, and cell loss relative to WT rats. Thus, the normal CA1 place cell spatial fidelity observed in 12-20 month-old AD rats contrasts with their memory impairments, CA2/3 place cell dysfunction, and neuropathology. The contrast is striking in part because CA3 pyramidal neurons are one of the most prominent sources of direct input to CA1 pyramidal neurons (Witter, Wouterlood, Naber, & Van Haeften, 2006) .
One potential explanation for the spared CA1 and impaired CA2/3 place cell function could be due to differing inputs to these regions from the entorhinal cortex, the main source of cortical inputs to the hippocampus (Lavenex & Amaral, 2000; Witter et al., 2006) . In particular, CA1 receives direct projections from layer III of entorhinal cortex, whereas CA2 and CA3 both receive direct projections from layer II of entorhinal cortex (Llorens-Martin et al., 2014; Steward & Scoville, 1976 Yassa, 2014) . Thus, the intact spatial fidelity of CA1 place cells of AD rats suggests that the dysfunctional input it is receiving from CA3 may be offset by intact inputs from layer III of the entorhinal cortex. This possibility is supported by previous studies that showed CA1 place cells were able to form normal place fields without input from CA3, but not without input from layer III of the entorhinal cortex (Brun et al., 2002 (Brun et al., , 2008 . Nevertheless, future studies would be needed to determine with more certainty whether differential pathology in layers II versus III of the entorhinal cortex would relate to differences between CA1 and CA2/3 place cell spatial fidelity in AD rats. Indeed, an alternate possibility is that entorhinal cortex inputs to both CA1 and CA2/3 are intact at 12-20 months of age in AD rats and that the CA2/ 3 dysfunction relates more closely to intrahippocampal pathology at this age (e.g., in upstream dentate gyrus or CA3 itself).
An important remaining question is how CA2/3 dysfunction in AD rats related to the memory impairment and disease progression. A straightforward interpretation is that pathological molecular processes related to AD (e.g., amyloid and/or tau pathology) led to neuronal dysfunction in CA2/3, which impaired AD rats' memory. It is also possible that the neuronal dysfunction in CA2/3 exacerbated the pathological progression. For example, prior studies have found that exciting hippocampal neurons of AD mice increases the secretion of soluble Ab (Noebels, 2011). Soluble Ab in turn can increase cellular excitability and can be toxic to cells (Findeis, 2007; Noebels, 2011; Palop et al., 2007) . The present data from extracellular recordings cannot speak directly to membrane dynamics, but one idea to pursue in future research is the possibility that dysfunctional activity of CA2/3 pyramidal cells early in AD could accelerate the disease progression in the hippocampus.
Recording hippocampus activity of AD rats at 6 months of age or younger, well before amyloid or tau pathology begins to increase, would help uncover if CA2/3 place cell dysfunction precedes and perhaps plays a causal role in the pathological progression of AD. (Booth et al., 2016; Cacucci et al., 2008; Cayzac et al., 2015; Cheng & Ji, 2013; Mably et al., 2017; Rubio et al., 2012; Zhao et al., 2014) . The current study also found hippocampal dysfunction in AD rats, but in contrast to these prior studies in mice, observed deficits only in CA2/3 place cells. The prior mouse studies did not report data for CA2 or CA3 pyramidal neurons, but in the present study CA1 place cells in 12-20 month-old AD rats showed good levels of spatial fidelity. One possibility for the discrepancy with respect to CA1 place cell fidelity between the current results and findings with AD mouse models is that the somewhat slower time course of disease progression in the AD rat model (Cohen et al., 2013) relative to some mouse AD models (see Hall & Roberson, 2012 ) created an opportunity to detect changes that occur earlier in the disease, before the pathological progression could cause ubiquitous dysfunction in brain memory circuits. If so, recordings from AD mice in both CA1 and CA3 regions at a very early stage of the disease would also be expected to show dysfunctional CA2/3 place cells prior to the onset of dysfunction in CA1 place cells.
In addition to differing age-related trajectories of disease progression between the Tg-F344 AD rat model and many mouse AD models, there are also several important genetic and pathological differences between rodent models of AD. The transgenic rat model of AD used in the current study expresses two genetic mutations (APPswe and PS1DE9) that are found in humans with familial AD and shows many of the same pathological features that are seen in human AD, including age-dependent robust tau pathology, markers of neuroinflammation, and cell death (Cohen et al., 2013) . Rats (Rattus novegicus) share six isoforms of tau protein with humans, whereas mice (Mus musculus) share three isoforms of tau with humans (Hanes et al., 2009; McMillan et al., 2008) . As a result, many of the mouse models of AD used to investigate hippocampal place cells have utilized tau mutations that are not found in humans with AD in order to induce tau pathology (e.g. Booth et al., 2016; Cheng & Ji, 2013; Mably et al., 2017) . It is unclear the extent to which these tau-related genetic differences between mice and rats can explain the differences in CA1 place cell findings between the current study in rat and past studies in mice, but the question will be worth pursuing in future studies aimed at understanding human AD.
4.3 | Administration of M 1 agonist influenced place cell spiking but not place cell spatial fidelity
Recent experimental evidence indicated that increasing M 1 muscarinic acetylcholine receptor activity reduced AD pathology and cognitive impairment in AD mice (Lebois et al., 2017) and increased spatial correlates in young WT rats (Lebois et al., 2016) . Thus, a second main question was whether oral administration of an M 1 -speicifc mAChR agonist (VU0364572) would ameliorate any AD-related hippocampal dysfunction. Although the M 1 agonist did not appreciably change any of the metrics related to spatial fidelity in which AD CA2/3 place cells were significantly impaired relative to WT CA2/3 place cells (spatial information scores, proportion of in-field firing, and place field area), the M 1 agonist did influence in-field firing rates and spike-phase modulation.
Specifically, there were no differences between AD and WT in the control condition for in-field firing rates and spike-phase modulation, yet differences emerged following administration of the M 1 agonist. For example, the M 1 agonist numerically increased the in-field firing rates of WT place cells but numerically decreased the in-field firing rates of AD place cells, suggesting that the impact of the drug depended on the functional state of the brain prior to administration. The effects of the M 1 agonist on in-field firing rates were not reflected in spatial information scores, perhaps because the effects on in-field firing rates were offset by effects on out-of-field firing rates such that the proportion of in-field firing was similar across drug conditions. VU0364572 was chosen for the present study in part because it is a direct agonist and can therefore activate the M 1 muscarinic receptor even if endogenous levels of acetylcholine were reduced. Nevertheless, one consideration for future studies is that chronic dosing of an M 1 mAChR agonist such as VU0364572 may be needed to impact AD progression (see Lebois et al., 2017) . Another consideration is the possibility that an M 1 positive allosteric modulator, which would augment the activity of endogenous and phasically-released acetylcholine at the M 1 receptor, might benefit AD-related hippocampal dysfunction in ways that the M 1 agonist VU0364572 did not. In any case, the M 1 agonist did influence spiking activity in the hippocampus, and the difference between genotypes, subregions, and various metrics of hippocampal function points to the usefulness of using in vivo electrophysiology to understand effects of potential drug therapies on brain function.
| C ONC LUSI ON
The slower-paced accumulation of AD-pathology in the TgF344 AD rat model (frank pathology by 16 months of age; Cohen et al., 2013 ) may be particularly useful for investigating early impairments in cellular and neural network dysfunction that occur before Ab plaques or tau pathology has spread extensively throughout the brain. For example, future studies could examine hippocampal spatial fidelity in AD rats as early as 6 months of age, when Ab plaques have not formed but soluble oligomeric fibrillar Ab and markers of inflammation are already elevated above age-matched WT controls (Cohen et al., 2013) . Moreover, recording studies in AD rats can benefit from decades of data on place cell function in healthy rat brains. Indeed, the current study highlighted the possibility that network dysfunction relatively restricted to the CA2/3 regions of the hippocampus may occur in AD before the peak of molecular and protein abnormalities, widespread brain dysfunction, and irreversible cell death occurs. Given that age is a major risk factor of the majority of "sporadic" AD cases in humans that are not linked to specific genetic mutations (Kukull et al., 2002) , future studies should investigate how age-related dysfunction interacts with dysfunction related to AD pathology. The results also pointed to the potential for using techniques like in vivo electrophysiology in AD rats to understand how function and dysfunction relate to neuropathology and how potential drug therapies might influence dynamic brain circuits.
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